Health and Medicine

Copolymer 1, also called glatiramer acetate, is an unusual therapeutic compound, a heterogeneous mix of polypeptides containing the four amino acids Y, E, A, and K in definite ratios but with no uniform sequence. Although its mode of action remains controversial, this preparation clearly helps retard the progression of human multiple sclerosis (MS) and of the related autoimmune condition, studied in mice, experimental autoimmune encephalomyelitis (EAE). Copolymer 1 is presented on class II MHC molecu

A group of anti-cancer agents that once produced dismal results in clinical trials could once again be a promising tool in fighting the deadly disease, thanks to research by a team of chemists at the University of Washington and in Germany.

The agents, called maytansinoids, were first discovered in the 1970s when scientists looked for tumor inhibitors in a rare Ethiopian plant. The same group of maytansinoids was later isolated from a new bacteria species. The compounds held great promise b

A new UCLA Neuropsychiatric Institute study shows for the first time that measurable changes in the front of the brain can predict the effectiveness of an antidepressant within days of treatment — weeks before a patient begins to feel better.

Using quantitative EEG, a non-invasive computerized measurement of brain wave patterns, the researchers discovered that specific changes in brain-wave activity precede clinical changes brought on by medication. The new findings, published in the July e

Depression investigators at The Research Institute of University Hospitals of Cleveland have zeroed in on the neurotransmitter serotonin, a brain chemical that regulates emotion. Their tactics: reduce serotonin levels in each study subject to learn who is vulnerable for developing major depression.

This new study, funded by the National Institute of Mental Health, is designed to help scientists better understand the role of serotonin in people who get major depression. By examining the way

Scientists at the University of North Carolina have successfully treated mice with hemophilia A using a new approach to gene therapy – RNA trans-splicing. The experimental procedure repairs a mutated section of the gene responsible for hemophilia A, a hereditary bleeding disorder.

Dr. Hengjun Chao, a research assistant professor at the UNC School of Medicine, Gene Therapy Center will present the new research Saturday June 8 in Boston at the Presidential Symposium of the American Society of

LGC, the UK`s leading independent provider of genetic testing services, has issued its first testing licence for the key DNA variant in the drug metabolising gene CYP2D6 to Orchid BioSciences Inc. LGC holds the exclusive commercialisation rights to the patented diagnosis of this `poor metaboliser` gene variation and, in granting this first licence, will make access to this beneficial technology available to leading companies internationally for the first time.

The gene CYP2D6 controls an enz